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Abstract
Background: Neuroblastoma is the most common extracranial solid malignancy in childhood, responsible for 15%
of all pediatric cancer deaths. It is an heterogeneous disease that does not always respond to classical therapy; so
the identification of new and specific molecular targets to improve existing therapy is needed. We have previously
demonstrated the involvement of the Notch pathway in the onset and progression of neuroblastoma. In this study
we further investigated the role of Notch signaling and identified Delta-like 1 (DLL1) as a novel molecular target in
neuroblastoma cells with a high degree of MYCN amplification, which is a major oncogenic driver in
neuroblastoma. The possibility to act on DLL1 expression levels by using microRNAs (miRNAs) was assessed.
Methods: DLL1 mRNA and protein expression levels were measured in three different neuroblastoma cell lines
using quantitative real-time PCR and Western Blot analysis, respectively. Activation of the Notch pathway as a result
of increased levels of DLL1 was analyzed by Immunofluorescence and Western Blot methods. In silico tools
revealed the possibility to act on DLL1 expression levels with miRNAs, in particular with the miRNA-34 family.
Neuroblastoma cells were transfected with miRNA-34 family members, and the effect of miRNAs transfection on
DLL1 mRNA expression levels, on cell differentiation, proliferation and apoptosis was measured.
Results: In this study, the DLL1 ligand was identified as the Notch pathway component highly expressed in
neuroblastoma cells with MYCN amplification. In silico analysis demonstrated that DLL1 is one of the targets of
miRNA-34 family members that maps on chromosome regions that are frequently deregulated or deleted in
neuroblastoma. We studied the possibility to use miRNAs to target DLL1. Among all miRNA-34 family members,
miRNA-34b is able to significantly downregulate DLL1 mRNA expression levels, to arrest cell proliferation and to
induce neuronal differentiation in malignant neuroblastoma cells.
Conclusions: Targeted therapies have emerged as new strategies for cancer treatment. This study identified the
Notch ligand DLL1 as a novel and attractive molecular target in childhood neuroblastoma and its results could help
to devise a targeted therapy using miRNAs.
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Background
Neuroblastoma is an embryonic tumor of the sympathetic
nervous system which arises during fetal or early postnatal
life from sympathetic cells derived from the neural crest
[1]. It is the most common solid extracranial malignancy
of childhood and is responsible for 15% of all pediatric
cancer deaths. Neuroblastoma is an extremely heteroge-
neous disease; tumors can spontaneously regress or differ-
entiate, even without therapy, or display a very aggressive
malignant phenotype that is poorly responsive to current
intensive multimodal therapy [2–4]. Despite high-dose
chemotherapy, surgery and radiotherapy, in half of cases
the tumor has a survival rate of less than 40% [5]. Unsatis-
factory response to classical therapies may be attributable
to the clinical, biological and histological heterogeneity of
“neuroblastomas”. Thus, the identification of novel select-
ive target molecules is needed, to improve existing therap-
ies and to develop new, specific, innovative and less
aggressive therapeutic approaches [6, 7]. Our previous
study recognized one of the molecular pathways involved
in neuroblastoma to be a component of the Notch signal-
ing pathway [8]. The Notch pathway is an highly con-
served cell signaling system that regulates cell fate
decisions during embryogenesis, modulates the differenti-
ated state of mature cells and is also one of the main fac-
tors in the regulation of “cancer stem cells” [9, 10]. Several
studies have demonstrated the importance of Notch sig-
naling in the tumor microenvironment and its involve-
ment in many aspects of the disease: the onset of tumor,
angiogenesis, the ability to invade tissues and metastasize
[11–16]. Depending on organ and tissue type, Notch sig-
naling can function either as a promoter to support tumor
development or as a suppressor to inhibit tumor growth.
Deregulated expression of Notch proteins, ligands, and
targets has been described in a multitude of solid tumors
including renal, lung, pancreatic, hepatocellular and gas-
tric carcinoma, melanoma and medulloblastoma [17].
Notch activation is responsible for increased growth and
proliferation of neuroblastoma cell lines. On the contrary,
Notch pathway downregulation by gamma-secretase in-
hibitors causes proliferation arrest and cell differentiation
[8]. In this study we wanted to investigate in detail the role
of Notch signaling in neuroblastoma and we analyzed the
role of Notch pathway components, three receptors
(Notch1, Notch 2 and Notch 3) and five canonical ligands
(Delta-like 1, Delta-like 2, Delta-like 4, Jagged 1 and
Jagged 2), in three neuroblastoma cell lines. We identified
DLL1 as the Notch pathway component highly expressed
in IMR-32 cells, a cell line with a high degree of MYCN
amplification. About 20% of neuroblastoma cases are
characterized by MYCN gene amplification, which has
been correlated with tumor progression and is routinely
used as a clinical biomarker for treatment stratification
[18, 19]. The correlation between Delta-like Notch ligand
expression and development of other tumors has already
been characterized. Overexpression of DLL1 was identi-
fied in choriocarcinoma [20] and hepatocellular carcinoma
[21], while Delta-like 4 (DLL4) expression was correlated
to tumor initiation and progression of glioblastoma [22],
poor prognosis in pancreatic cancer [23] and colon cancer
[24]. We evaluated the possibility to act on the expression
of DLL1 by using miRNAs. During the past decades the
involvement of miRNAs in several human diseases, in-
cluding cancer, has been intensively investigated. miRNAs
are a class of small, 19–22 nucleotides, non-coding
endogenous single-stranded RNAs that act as post-
transcriptional regulators of specific messenger transcripts
(mRNAs), resulting in targeted degradation or suppression
of gene expression [25, 26]. More than 4469 miRNAs have
been identified in Homo sapiens, of which 1881 are pre-
cursors and 2588 are mature (miRBase, Release 21: June
2014) and most of these miRNAs are highly conserved
across species. It has been reported that miRNAs are able
to control more than 60% of human protein-coding genes
[27, 28]. In physiologic conditions miRNAs are key regula-
tors involved in biological processes such as development,
proliferation, differentiation, migration, neuroplasticity,
survival and death. miRNAs dysregulation contributes to
the onset of different pathologies such as heart disease,
diabetes, mental disorders and cancer. Because 50% of
miRNAs genes are located at genomic sites associated
with cancer-specific chromosomal rearrangements and
because of the proximity of their genes to chromosomal
breakpoints, miRNAs have been associated with tumori-
genesis. In some cancer types miRNAs appear to be up-
regulated and are thus thought to act as oncogenes, while
they are downregulated in other types of cancers, which
may be indicative of a tumor suppressor function.
miRNAs expression is dynamic: many miRNAs are
deregulated in early stages of tumor development and up-
regulated during cancer progression, which underscores
the importance of the cellular microenvironment [29].
miRNAs can be used as biomarkers to discriminate cancer
from normal tissue, to diagnose the onset of a tumor, to
indicate the degree of dissemination and to monitor the
response to drug treatments, or as therapeutic targets in
the design of a real “miRNA-based therapy” [28]. In silico
analyses suggest that DLL1 is one of the targets of the
miRNA-34 family; miRNA-34a maps to the distal region
of chromosome 1p which is commonly deregulated or de-
leted in neuroblastoma (www.mirbase.org). miRNA-34a
can antagonize many different oncogenic processes by
regulating genes that function in various cellular pathways.
The anti-oncogenic activity of miRNA-34a has been dem-
onstrated in cancer cells of the lung [30, 31], pancreas [32,
33], brain [34, 35], ovary [36], prostate [37] as well as in
lymphoma and leukemia [38]. miRNA-34a inhibits the
propagation properties of tumor-initiating cells derived
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from medulloblastoma [39] and it is downregulated in
glioblastoma tissues, where its overexpression could sup-
press cell proliferation and induce apoptosis, indicating
that this miRNA may act as tumor suppressor also in this
type of tumor [40]. miRNA-34b is significantly downregu-
lated in prostate cancer and its reconstitution induced
anti-proliferative and antimigratory effects and suppressed
tumor growth in an in vivo xenograft nude mouse model,
suggesting the tumor suppressor function of this miRNA
[41]. Also, in breast cancer, miRNA-34b acts as an onco-
suppressor regulating the complex estrogenic pathway,
which could lead to the development of new therapeutic
strategies [42]. The miRNA-34 family was the most exten-
sively studied miRNAs in neuroblastoma and Welch and
colleagues were the first to report that miRNA-34a was
generally expressed at lower levels in unfavorable primary
neuroblastomas and cell lines compared to normal ad-
renal tissue. miRNA-34a induced cell cycle arrest, apop-
tosis, and significantly reduced tumor growth in an in vivo
orthotopic murine model of neuroblastoma [35]. Our data
indicate that, within the miRNA-34 family, miRNA-34b
induced significant downregulation of DLL1 mRNA ex-
pression levels, cell differentiation and arrested cell prolif-
eration in IMR-32 neuroblastoma cells. This study
identified Notch ligand DLL1 as a new and specific mo-
lecular target in childhood neuroblastoma, suggesting that
miRNAs could be a novel therapeutic tool to develop an
effective strategy to attack “DLL1 positive” neuroblastoma.
Methods
Cell lines
The human SH-SY5Y neuroblastoma cell line (DSMZ)
was cultured in a 1:1 mixture of Ham’s F12 nutrient and
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich)
supplemented with 10% fetal bovine serum (FBS, Sigma-
Aldrich), 2 mM L-glutamine, 50 mg/mL penicillin, and
100 mg/mL streptomycin (Sigma-Aldrich). The IMR-32
neuroblastoma cell line (DSMZ) and the KELLY neuro-
blastoma cell line (Sigma-Aldrich) were grown in RPMI
medium (Sigma-Aldrich) supplemented with 10% FBS
(Sigma-Aldrich), 2 mM L-glutamine, 50 mg/mL penicil-
lin, 100 mg/mL streptomycin (Sigma-Aldrich), and 1×
MEM nonessential amino acid solution (Sigma-Aldrich).
All the cell lines were grown at 37 °C in a 95% air–5%
CO2 humidified incubator.
siRNAs and miRNAs transient transfection
siRNA probes targeted to the DLL1 ligand were pur-
chased from Dharmacon (Dharmacon, Inc., Lafayette,
CO, USA). Human-specific DLL1 interference was per-
formed using an Accell SMARTpool siRNA mixture
containing a mixture of four siRNAs targeting the DLL1
gene. A non-targeting Accell siRNA pool was used as a
control in siRNA transfection experiments. IMR-32
neuroblastoma cells were transfected with Accell siR-
NAs, using Hi-perfect transfection reagent (Qiagen) in
culture medium with 3% normal serum 1 day after seed-
ing. Cells were maintained in culture for three more
days after transfection with 20 nM siRNA. IMR-32
neuroblastoma cells were transfected with different
miRNA-34 (miRNA-34a, miRNA-34b, miRNA-34c, Qia-
gen) and miRNA-210 (Qiagen), as internal control, using
Hi-perfect transfection reagent (Qiagen) in culture
medium with 3% normal serum 1 day after seeding. Cells
were maintained in culture for three more days after
transfection with 10 nM miRNAs.
Quantitative real-time PCR
Quantitative real-time PCR (RT-qPCR) was executed as
described below. The total RNA was isolated from SH-
SY5Y, KELLY and IMR-32 neuroblastoma cells using the
RNeasy kit (Qiagen) and digested with the RNase-Free
DNase set (Qiagen), according to the manufacturer’s
protocol. One microgram of total RNA was transcribed
into complementary DNA (cDNA) using murine
leukemia virus reverse transcriptase (Promega Italia) and
oligo(dT)15-18 as a primer (final volume: 50 μl). The
oligonucleotide sequences of the primers used are as fol-
lows: N-Myc forward primer 5′-CGA CCA CAAGGC
CCT CAG TA-3′, reverse primer 5′-CAG CCTTGG
TGT TGG AGG AG-3′; DLL1 forward primer 5′-
ACGAATGCTGCTGCTGAAGAGGAGGGA-3, reverse
primer 5′-AACTGTCAATAGTGCAACGGCGAC-3′;D
LL3 forward primer 5′-AGCGTCACACAATCACGA
AG-3′, reverse primer 5′-TGGTATGAACCAGAGC-
TACCG-3′; DLL4 forward primer 5′-AACTGCCCTT
CAATTTCACCT-3′, reverse primer 5′-GCTGGTTT
GCTCATCCAATAA-3′; Jagged 1 forward primer 5′-
AGACATCGATGAATGCGTCA-3′, reverse primer 5′-
CCACAGACGTTGGAGGAAAT-3′; Jagged 2 forward
primer 5′-TGGCACTCGCTGTATGAAAG-3′, reverse
primer 5′-AGGGCCACATCAATAACCAG-3′; GAPDH
forward primer 5′-GAG TCA ACG GAT TTG GTC
GT-3′, reverse primer 5′-TTG ATT TTG GAG GGA
TCT CG-3′. Amplification and detection were per-
formed with the iCYCLER iQ Real Time PCR Detection
System (BioRad Italia, Milan, Italy); the fluorescence sig-
nal was generated by SYBR Green I. Samples were run
in triplicate in a 25 μl reaction mix containing 12.5 μl 2×
SYBR Green Master Mix (BioRad Italy), 12.5 pmol of
each forward and reverse primer and 2 μl of diluted
cDNA. The PCR program was initiated by 10 min at
95 °C followed by 40 cycles, each for 15 s at 95 °C and
1 min at 60 °C. Gene expression levels were normalized
to GAPDH expression and data are presented as the fold
change in target gene expression in drug-treated cells
normalized to the internal control gene (GAPDH) and
relative to untreated cells. Results were estimated as Ct
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values; the Ct was calculated as the mean of the Ct for
the target gene minus the mean of the Ct for the
internal control gene. The Ct represented the mean dif-
ference between the Ct of untreated cells minus the Ct
of treated cells. The N-fold differential expression in the
target gene of drug-treated cells compared with un-
treated cells was expressed as 2- ΔΔCt. Data analysis and
graphics were performed using Graph Pad Prism 5
software and the results of experiments were run in
triplicate.
Western blot analysis
Total cell lysates were prepared by scraping the cells in lysis
buffer (50 mM Tris pH 7.6, 150 mM NaCl, 2 mM EDTA,
0.5% NP40 with a cocktail of protease inhibitors). For
Western blot analysis, 15 μg of total proteins were electro-
phoresed onto 10% SDS-PAGE and transferred to nitrocel-
lulose paper. Filters were incubated with anti-Notch 1
antibody (Sigma-Aldrich; 1:1000), anti-Neuronal Nuclei
antibody (Millipore; 1:1000), anti-β III tubulin (Promega;
1:1000) and anti-Glyceraldehyde-3-phosphate dehydrogen-
ase antibody (Millipore; 1:500) as loading control. After
washing, membranes were incubated with HRP-conjugated
antimouse and antirabbit secondary antibody (Dako;
1:1500) and a chemiluminescence blotting substrate kit
(Amersham Biosciences) was used for immunodetection.
Evaluation of immunoreactivity was performed on immu-
noblots by densitometric analysis using the Quantity One
analysis software (BioRad Laboratories GmbH).
Immunofluorescence and morphometric analysis
Immunofluorescence and morphometric analyses were
executed as described below. SH-SY5Y cells were plated
with a density of 75 × 103/well in a 24 wells plate, grown
on a glass coverslip (coated with poly-l-lysine, Sigma-
Aldrich); IMR-32 cells were plated with a density of 50 ×
103/well and grown on a glass coverslip coated with col-
lagen IV (BD Bioscience). Cells were fixed in ice-cold
methanol (Sigma-Aldrich), then washed and incubated
in Phosphate Buffered Saline (PBS, Sigma-Aldrich) con-
taining 1% of Bovine Serum Albumin (BSA, Sigma-
Aldrich) and 0.2% Triton X 100 overnight at 4 °C with a
polyclonal anti-β III tubulin (Sigma-Aldrich, 1:600),
monoclonal anti-Notch 1 (Sigma-Aldrich, 1:1000). After
rinses, cells were incubated with Alexa Fluor® 488 (Life
Technologies, 1:400) anti rabbit secondary antibody and
CY™3-conjugated anti-mouse secondary antibody (Jack-
son Immunoresearch Laboratories INC.,1:500) in PBS
for 1 h at room temperature. For morphological evalu-
ation, slices were mounted and examined by a ZEISS
LSM 510 META confocal laser-scanning microscope
(Carl Zeiss, Germany). Images were processed using
LSM5 image examiner software (Zeiss). The percentage
of morphologically differentiated cells was determined
by analyzing at least 10 fields for each treatment; cells
with neurites ≥50 μm in length were considered as
differentiated.
Flow Cytometry for analysis of cell cycle and apoptosis
For cell cycle analysis, cells were harvested at the com-
pletion of the miRNAs treatments and washed with
phosphate-buffered saline (PBS; pH 7.4) before being
fixed with 70% ethanol on the wheel for 15 min at 4 °C.
Subsequently, the cells were centrifuged at 4500 rpm for
5 min at 4 °C, washed with phosphate-buffered saline
and were resuspended in 600 μl of 0,1% sodium citrate
(Sigma-Aldrich), 50 μg/ml of propidium iodide (PI,
Sigma-Aldrich) and 10 μg/ml of Ribonuclease A (Sigma-
Aldrich) for staining cellular DNA. The cellular DNA
content was then analyzed using a MACS Quant Flow
Cytometer (Miltenyi Biotec). Data analysis was carried
out using FlowJo software. For the apoptosis analysis,
after treatment with miRNAs 10 nM, cells were washed
with PBS and stained with Annexin V-FITC and PI using
the Apoptosis Detection Kit (Bender Medsystems) ac-
cording to the manufacturer’s protocol. Annexin-positive
cells were counted using a MACS Quant Flow Cyt-
ometer (Miltenyi Biotec) within 1 h after staining. Data
analysis was carried out using FlowJo software.
Statistical analysis
Statistical analyses were performed by one-way analysis of
variance followed by Bonferroni’s multiple comparison
test as post hoc analysis. Data are presented as the
mean ± Standard Error Mean (S.E.M). Probabilities <0.05
and <0.001 were considered a significant difference.
Results
DLL1 is the notch pathway component highly expressed
in MYCN amplified neuroblastoma cells
At first, the role of Notch pathway components was in-
vestigated in neuroblastoma cell lines with different
MYCN gene amplification degree, which is related to ag-
gressiveness and malignant phenotype. RT-qPCR was
performed in three cell lines: SH-SY5Y cell line with low
degree of MYCN amplification, IMR-32 and KELLY with
high degree of MYCN amplification [43].The N-Myc
mRNA expression levels were established by RT-qPCR,
that confirmed a barely detectable N-Myc expression in
SH-SY5Y cells and a higher N-Myc expression levels in
KELLY and IMR-32 cells (Fig. 1a). The mRNA expres-
sion levels of three Notch receptors (Notch 1, Notch 2
and Notch 3) and five Notch ligands (Delta-like 1, Delta-
like 3, Delta-like 4, Jagged 1 and Jagged 2) were analyzed
by RT-qPCR and we identified DLL1 as the Notch path-
way component highly expressed in IMR-32 cells (Fig.
1b). Receptors were also analyzed but uniformity was
not found among the three cell lines (Additional file 1).
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DLL1 protein expression was also analyzed by immuno-
fluorescence that confirmed the high ligand levels in
IMR-32 cells compared with SH-SY5Y cell line (Fig. 1c).
High DLL1 ligand expression levels are associated with
notch pathway activation in IMR-32 neuroblastoma cells
To verify if DLL1 increased levels leads to an effective
Notch pathway activation, the expression of NICD pro-
tein (Notch Intracellular Domain, Notch 1 activated
form) in SH-SY5Y and IMR-32 neuroblastoma cells was
analyzed. SH-SY5Y and IMR-32 cells were cultured for
48 h in complete medium and then analyzed by im-
munofluorescence. A stronger Notch activation was
found in IMR-32 cells compared to SH-SY5Y (Fig. 2a).
This result was confirmed by Western blot and densito-
metric analysis, showing a significant increase of NICD
protein level in IMR-32 cell line (Fig. 2b, c).
Selective DLL1 downregulation by siRNA induces
neuroblastoma cell differentiation
Since DLL1 was identified as the Notch pathway compo-
nent most expressed in IMR-32 neuroblastoma cells,
and since DLL1 increased levels lead to an effective
Notch pathway activation, we investigated DLL1 molecu-
lar targeting by observing the effects of DLL1 gene silen-
cing via RNA interference technique in neuroblastoma
cells. First, the efficacy of various siRNAs at different
concentrations (5 nM, 10 nM, 20 nM and 40 nM) was
assessed in terms of their ability to induce significant
DLL1 downregulation. We identified siRNA 5 at the
concentration of 20 nM as the most capable to signifi-
cantly downregulate DLL1 mRNA expression levels;
siRNA – (non-targeting siRNA pool) 20 nM was used as
scrambled negative control (Additional file 2). To study
the effect of siRNA on neuroblastoma cell differenti-
ation, IMR-32 cells were transfected with siRNA 5
20 nM and cells were analyzed by immunofluorescence.
Confocal microscopy analysis showed that DLL1 down-
regulation by siRNA 5 induced neuronal differentiation,
characterized by changes in cell morphology such as
longer neurites, as obtained with 13-cis retinoic acid
(Fig. 3a). Retinoic acid was used as a positive control be-
cause it is a potent cellular differentiation agent able to
induce growth inhibition and cell differentiation in
normal and cancer cell types. Retinoic acid is cur-
rently used in neuroblastoma treatment, in association
with standard therapeutic protocols, as neoadjuvant
agent [44]. It is interesting and significant that DLL1
downregulation induced a cell differentiation compar-
able to the effect obtained with 13-cis retinoic acid. A
quantitative analysis of morphological differentiation
confirmed that DLL1 downregulation induced a statis-
tically significant increase in the number of differenti-
ated cells (Fig. 3b).
Fig. 1 Analysis of Notch ligands expression in neuroblastoma cells with different MYCN gene amplification. a RT-qPCR analysis of N-Myc mRNA
expression levels in SH-SY5Y, KELLY and IMR-32 neuroblastoma cell lines. b RT-qPCR analysis of the five mammalian Notch ligands in SH-SY5Y,
KELLY and IMR-32 neuroblastoma cell lines. c Immunofluorescence analysis of DLL1 protein expression in SH-SY5Y and IMR-32 neuroblastoma
cells. *p < 0.05 vs SH-SY5Y cell line
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DLL1 is downregulated in IMR-32 neuroblastoma cells
treated with miRNA-34b
In silico analysis using Target Scan 6.2 (Released June
2012) predict that the DLL1 is a potential target of
miRNA-34 family members. IMR-32 neuroblastoma cells
were transfected with miRNA-34 family members
(miRNA-34a, miRNA-34b, miRNA-34c) and miRNA-
210 as internal control. miRNA-210 was chosen as in-
ternal control because in silico analysis has shown that it
is not correlated to Notch signaling. miRNA-210 expres-
sion is related to diseases such as lung adenocarcinoma
[45] and cerebral ischemia [46]. Cells were transfected
with the miRNAs at three different concentrations (5 ,
10 and 20 nM) and RT-qPCR analysis of DLL1 mRNA
expression levels showed that in cells treated with
miRNA-34b, at the concentration of 10 nM, it was
observed a significant downregulation of DLL1 mRNA
expression levels (Fig. 4). This data suggest an important
role of miRNA-34b in DLL1 downregulation. At concen-
trations of 5 nM and 20 nM, no significant differences
between control and treated cells were found. We ob-
served that the 5 nM concentration had no effects, while
20 nM concentration was toxic for cells which showed
clear signs of cell suffering, and the analysis on cell ex-
tracts of RNA revealed no differences in expression levels.
miRNA-34b induces differentiation in IMR-32 neuroblast-
oma cells
The possible morphological changes after miRNAs
transfection on IMR-32 neuroblastoma cells were evalu-
ated. Analysis by confocal microscopy showed that
miRNA-34b transfection induced significant cellular dif-
ferentiation, characterized by longer neurites (Fig. 5a),
increasing the number of differentiated cells compared
to control (Fig. 5b). Morphological analysis was accom-
panied by biochemical patterns resembling the neuronal
phenotype. We therefore measured the levels of neur-
onal specific markers including Neuronal Nuclei protein
(Neu N) and β III tubulin by Western blot. Protein
expression levels of Neu N were strongly increased after
Fig. 2 Analysis of Notch pathway activation in neuroblastoma cells with different MYCN gene amplification. SH-SY5Y and IMR-32 cells were
chosen as the two cell lines with the lowest and the highest N-Myc mRNA expression. a Confocal analysis of NICD expression levels in SH-SY5Y
and IMR-32 cells. β III tubulin antibody (green) was used as neuron marker; NICD antibody (red) showed a typical nuclear localization, indicative of
Notch activation. b Western blot analysis of NICD protein expression in SH-SY5Y and IMR-32 cells. c Densitometric analysis of NICD expression
levels in SH-SY5Y and IMR-32 cells using Quantity One analysis software. *p < 0.05 vs SH-SY5Y cell line
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miRNA-34b treatment (Fig. 6a); the protein expression
levels of β III tubulin were also increased even if the data
was not statistically significant (Fig. 6b). These results
suggest that miRNA-34b may function as a cell fate
regulator, which modulates early cell differentiation in
IMR-32 neuroblastoma cells.
miRNA-34 family members induce cell proliferation arrest
in IMR-32 neuroblastoma cells
The ability of miRNAs to arrest cell proliferation was
assessed by cell cycle analysis. miRNA-34b induced an in-
crease in the number of cells in G0/G1 phase (*p < 0.001)
and a decrease in the number of cells in S phase
(**p < 0.001) of the cell cycle, compared to respective con-
trol. Other members of miRNA-34 family have such effects.
The data indicate that the treatment with all miRNA-34
family members blocked the cells in the G0/G1 phase, de-
creasing the number of proliferating tumoral cells (Fig. 7).
The effect of miRNA-34b is peculiar and specific for differ-
entiation pathway and not for cell proliferation arrest.
miRNA-34 family members do not induce apoptosis in
IMR-32 neuroblastoma cells
Finally a possible apoptotic effect of miRNAs on IMR-32
neuroblastoma cells was analyzed. Cytofluorimetric ana-
lysis, by Annexin V-positive cells, revealed that members
of the miRNA-34 family do not induce apoptosis in the
Fig. 4 RT-qPCR analysis of DLL1 mRNA expression levels in IMR-32
neuroblastoma cell line. Analysis of DLL1 mRNA expression levels
after Authors’ contribution3 days of transfection with all miRNA-34
family members and with miRNA-210. *p < 0.05 vs control
Fig. 3 Analysis of siRNA DLL1 and 13-cis retinoic acid treated IMR-32 neuroblastoma cell line. a Confocal analysis of siRNA DLL1 and 13-cis retinoic acid in
IMR-32 neuroblastoma cells after 3 days of transfection. β III tubulin antibody was used as neuron marker. b Morphometric analysis of cell differentiation
induced by siRNA DLL1 and 13-cis retinoic acid. Neuronal differentiation was evaluated by measuring neurite length. The percentage of differentiated cells
was calculated, considered as cells with neurites ≥50 μM in length in IMR-32 cells. *p < 0.05 vs control
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IMR-32 neuroblastoma cell line (Fig. 8a, b). These data
suggest that miRNAs treatments drive the cells in G0/
G1 phase towards a differentiation profile instead to cell
death.
Discussion
In the present study Notch ligand DLL1 emerged as a
novel molecular target in childhood neuroblastoma and
miRNAs could be an innovative tool to attack “DLL1
positive” tumors. The DLL1 ligand was observed to be
the most expressed Notch pathway component in
MYCN amplified neuroblastoma cells and its downregu-
lation, with miRNAs, induced differentiation and an ar-
rest of cell proliferation. Recently, the focus of cancer
research has been the identification of new molecular
targets which will permit to act with more specific and
effective drugs, thereby paving the path towards innova-
tive therapeutic strategies. The involvement of the Notch
pathway in tumors, including neuroblastoma, has previ-
ously been described; our group has demonstrated that
Notch activation is responsible for growth and prolifera-
tion of neuroblastoma cells, while its inhibition causes
proliferation arrest and cell differentiation [8]. DLL1 is a
transmembrane ligand of the Notch signaling pathway
that is also overexpressed in other types of tumor, such
as choriocarcinoma [20] and medulloblastoma [39],
indicating a probable strong involvement of this Notch
pathway component in the onset of such tumors. Fur-
thermore, DLL1 is not only implicated in tumorigenesis,
it is also involved in sympathetic ganglia development
where the protein maintains the proliferation state of
embryonal cells [47, 48]. In the present study DLL1 was
found to be highly expressed in IMR-32 cells, a cell line
with a high degree of MYCN gene amplification. The
MYCN proto-oncogene plays an important role in
neuroblastoma development; about 30%-40% of ad-
vanced stage tumors exhibit MYCN amplification, which
has been correlated to rapid tumor progression, drug re-
sistance and poor outcome [49, 50]. Thus, these data
probably suggest that DLL1 expression is dependent on
the degree of MYCN gene amplification, although
further work is needed to demonstrate this. Zhao and
colleagues had previously demonstrated that Delta-like 3
Fig. 5 Analysis of miRNA-34b transfection in IMR-32 neuroblastoma
cells line. a Confocal analysis of miRNA-34b transfection in IMR-32
neuroblastoma cells after 3 days of transfection. β III tubulin antibody was
used as neuron marker. b Morphometric analysis of cell differentiation
induced by miRNAs transfection. IMR-32 neuroblastoma cells underwent 3
days of transfection and then neuronal differentiation was evaluated by
measuring neurite length. The percentage of differentiated cells was
calculated, considered as cells with neurites ≥50 μM in length in IMR-32
cells. *p < 0.05 vs control
Fig. 6 Western Blot analysis of IMR-32 neuroblastoma cell line. Western
Blot analysis of Neu N (a) and β III tubulin (b) protein expression levels
after 3 days of miRNAs transfection. *p < 0.05 vs control
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(DLL3) is a direct transcriptional target of N-Myc, iden-
tifying a new “N-Myc-DLL3” pathway as a mediator of
neural development in brain [51]. Recently, miRNAs
have emerged as a new promising therapy in many dif-
ferent diseases, including cancers, thanks to their ability
to modulate selective molecules at post-transcriptional
level [52, 53]. miRNAs act as fine regulators of cancer
development, functioning as oncogenes or tumor sup-
pressor, and they can be used to form the new “miRNA-
based therapy” for cancer [54, 55]. In silico analysis
showed that DLL1 ligand is one of the targets of
miRNA-34 family, which is known for its potential
tumor suppressing role in several cancers including
neuroblastoma, glioblastoma, and medulloblastoma. In
neuroblastoma tissues and cell lines, members of the
miRNA-34 family are expressed at very low levels and
their ectopic expression induce cell cycle arrest, apop-
tosis, and a reduction of tumor growth in vivo [56]. The
data suggest a role for miRNA-34a as a potential tumor
suppressor in neuroblastoma [35], and for miRNA-34b
as an oncosuppressor in in vitro prostate cancer models
and breast cancer [41, 42]. In this study miRNA-34b was
Fig. 7 Cell cycle analysis of IMR-32 neuroblastoma cell line. Cell cycle analysis, by Flow Cytometer, of IMR-32 cells after 3 days of miRNAs transfection.
*p < 0.0001 vs G0/G1 phase control. **p < 0.0001 vs S phase control
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able to significantly downregulate DLL1 ligand and to
induce neuronal differentiation, much more than other
components of the miRNA-34 family. This divergence
may be due to the fact that the sequences of miRNA-34a
and miRNA-34b differ for few nucleotides and the dif-
ferent actions of miRNAs probably depend on the tumor
microenvironment, cell lines used, as well as the choice
of in vivo tumoral model. One of the mechanisms of ac-
tion of miRNAs is the induction of apoptosis, through
the activation of a caspase-dependent apoptotic pathway,
and the inhibition of proliferation [36]. The results ob-
tained in IMR-32 neuroblastoma cell line demonstrate
that members of the miRNA-34 family are able to in-
duce a significant arrest of tumor cell proliferation but
not to induce apoptosis. Probably cells blocked in G0/
G1 phase move towards a path of cell differentiation and
not apoptotic death. Whether miRNAs induce apoptosis
presumably depends on the cellular context and on the
expression levels of the miRNA-34 target proteins
involved in the regulation of apoptosis.
Conclusions
This study was conducted in order to identify the Notch
pathway components highly involved in neuroblastoma
genesis and progression. DLL1 emerged to be the ligand
highly expressed in cell lines with high MYCN gene
amplification, indicative of increased degree of malig-
nancy. Downregulation of the ligand inhibited cell prolif-
eration and induced differentiation, suggesting a pro-
oncogenic role for DLL1. The ligand DLL1 was also
shown to be a potential target of miRNA-34b, opening
the possibility to use miRNAs-based therapy. This idea
could be supported by the observation that miRNAs
treated cells also showed proliferation arrest and neurite
elongation. In conclusion, the data collected point to
DLL1 Notch ligand as a new and attractive molecular
target in childhood neuroblastoma, and we propose
miRNAs as new potential therapy to act on high DLL1
expression. There is strong evidence in the literature
supporting the idea that miRNAs could be a new, poten-
tially more effective and specific therapeutic tools, com-
pared with current medical strategies. This study also
contributes to the knowledge concerning the role of the
Notch pathway in neuroblastoma, shedding light on
mechanisms and molecules involved in neuroblastoma
pathogenesis.
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